Schubert & CO Biomarin Pharmaceutical Inc Transaction History

Schubert & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	BUY	$87.74 - $117.27 $87 - $117	1 Added 1.79%	57 $5,000
Q4 2022 Jan 31, 2023	SELL	$80.93 - $108.63 $1,375 - $1,846	-17 Reduced 23.29%	56 $5,000
Q3 2022 Oct 21, 2022	BUY	$82.16 - $96.94 $2,793 - $3,295	34 Added 87.18%	73 $6,000
Q2 2022 Aug 01, 2022	BUY	$71.48 - $86.85 $1,644 - $1,997	23 Added 143.75%	39 $3,000
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $297 - $370	4 Added 33.33%	16 $1,000
Q4 2021 Jan 28, 2022	BUY	$71.72 - $91.47 $860 - $1,097	12 New	12 $1,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.